SCHEMBL707640

SCHEMBL707640

COC(=O)c1ccc(C=Cc2cnc3ccccc3n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.54
NPC1 O15118 8/20 0.54
KMT2A Q03164 6/20 0.52
ALDH1A1 P00352 6/20 0.52
MAPT P10636 6/20 0.52
KDM4E B2RXH2 5/20 0.52
HPGD P15428 3/20 0.52
GLA P06280 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
SMN1; SMN2 Q16637 7/20 0.49
MEN1 O00255 5/20 0.49
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49
PTPN1 P18031 1/20 0.48
DRD2 P14416 1/20 0.47
PAX8 Q06710 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
PKM P14618 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL707639 1.00 RAB9A (0.54) RAB9ANPC1KMT2AALDH1A1MAPT
SCHEMBL709375 0.83 RAB9A (0.52) RAB9ANPC1KMT2AALDH1A1MAPT
SCHEMBL709374 0.83 RAB9A (0.52) RAB9ANPC1KMT2AALDH1A1MAPT
SCHEMBL9836123 0.83 KDM4E (0.66) RAB9ANPC1KMT2AALDH1A1MAPT
SCHEMBL9836128 0.83 KDM4E (0.66) RAB9ANPC1KMT2AALDH1A1MAPT
SCHEMBL2399629 0.82 KDM4E (0.66) RAB9ANPC1KMT2AALDH1A1MAPT
SCHEMBL2399632 0.82 KDM4E (0.66) RAB9ANPC1KMT2AALDH1A1MAPT
SCHEMBL12923109 0.81 PAX8 (0.63) RAB9ANPC1KMT2AALDH1A1MAPT
SCHEMBL510062 0.79 NPC1 (0.55) RAB9ANPC1KMT2AALDH1A1MAPT
SCHEMBL708541 0.79 NPC1 (0.55) RAB9ANPC1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20040242615-A1 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242615-A1 Utilities of olefin derivatives APOL1, NR1H2, APOB RAB9A 4723/4885NPC1 19/4885KMT2A 3382/4885
US-20090036457-A1 Utilities of olefin derivatives APOL1, APOB, NR1H2 RAB9A 4606/4885NPC1 48/4885KMT2A 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.